[{"id":"e1eec305-12a1-4b55-aca1-9621bccaf5e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836324","created_at":"2023-05-01T15:04:34.613Z","updated_at":"2025-02-25T14:03:30.395Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05836324","lead_sponsor":"Incyte Corporation","biomarkers":" HER-2 • BRAF • ER • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • BRAF • ER • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INCA33890"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 07/24/2023","start_date":" 07/24/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"}]